Evidence map›Paper›PMID 28978147›Full record

ArticleOncotarget2017

Prognostic significance of GSTP1 in patients with triple negative breast cancer.

Guanglei Chen, Hao Zhang, Lisha Sun, Yanlin Jiang, Zhen Xu, Huizi Gu, Hong Xu, Jie Yang, Yining Wang, Tiantian Xu and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Guanglei Chen *Department of Breast Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Hao Zhang *Department of Breast Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Lisha Sun *Department of Surgical Oncology, The First Hospital of China Medical University, Shenyang 110013, China.
Yanlin JiangDepartment of Breast Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Zhen XuDepartment of Breast Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Huizi GuDepartment of Internal Neurology, The Second Hospital of Dalian Medical University, Dalian 116027, China.
Hong XuCancer Hospital of China Medical University, Shenyang 110042, China.
Jie YangDepartment of Breast Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Yining WangDepartment of Breast Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Tiantian XuDepartment of Breast Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Yingchao ZhangDepartment of Breast Surgery, The Second Hospital of JiLin University, Changchun 130041, China.
Caigang LiuDepartment of Breast Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China.
China Medical University · CNSecond Affiliated Hospital of Dalian Medical University · CNSecond Affiliated Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies showed that glutathione S-transferase Pi 1 (GSTP1) is a critical metabolic driver that is heightened specifically in triple negative breast cancer (TNBC) and drives breast cancer pathogenicity. This study focuses on investigating the relationship between the expression of the GSTP1 protein and TNBC metastasis and prognosis in China.

resultsChi-square and Fisher's exact tests showed that tumor size (P=0.023) and clinical stage (P=0.049) were significantly associated with GSTP1 expression. Patients with high GSTP1 expression exhibited an improved survival rate compared with patients with low GSTP1 expression, but the difference was not statistically significant (P=0.437). On multivariate analysis, clinical stage proved to be an independent prognostic factor for survival in breast cancer. MATERIALS AND

methodsA total of 175 patients with histologically confirmed TNBC, who also underwent radical surgery between January 2008 and November 2011 at the Liaoning Cancer Hospital, were enrolled. Immunohistochemistry was used to detect GSTP1 expression in breast cancer tissue from 175 patients. The correlations between GSTP1 expression and other parameters were evaluated using the Chi-square and Fisher's exact tests. Univariate and multivariate Cox regression analyses were performed to assess independent prognostic factors for survival. Associations of GSTP1 expression with clinical stage and prognosis were analyzed using Kaplan-Meier survival curves.

conclusionsTumors with high GSTP1 protein expression were independently associated with low clinical stages in TNBC patients in China. The expression of the GSTP1 protein may be a novel prognosis marker for TNBC patients in China.

Indexed as

breast cancerGSTP1prognosis

Identifiers

PMID28978147
PMCPMC5620287
OpenAlexW2739483649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.